2012
Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907)
Ruddy KJ, Pitcher BN, Archer LE, Cohen HJ, Winer EP, Hudis CA, Muss HB, Partridge AH. Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907). Annals Of Oncology 2012, 23: 3075-3081. PMID: 22767584, PMCID: PMC3501229, DOI: 10.1093/annonc/mds133.Peer-Reviewed Original ResearchConceptsEarly-stage breast cancerBreast cancerMedication calendarOral cyclophosphamideStandard chemotherapyStage I-IIIB breast cancerSelf-reported adherenceCase report formsToxic effectsAdjuvant chemotherapyCALGB 49907Febrile neutropeniaOral CMFNode negativityOlder patientsStandard therapyMedian ageSuperior tolerabilityRandomized trialsCyclophosphamide dosesAverage adherenceOlder womenCyclophosphamideChemotherapyConsecutive days
2008
Advances in Adjuvant Endocrine Therapy for Postmenopausal Women
Lin NU, Winer EP. Advances in Adjuvant Endocrine Therapy for Postmenopausal Women. Journal Of Clinical Oncology 2008, 26: 798-805. PMID: 18258989, DOI: 10.1200/jco.2007.15.0946.Peer-Reviewed Original ResearchConceptsPostmenopausal womenAromatase inhibitorsEndocrine therapyBreast cancerHormone receptor-positive breast cancerHormone receptor-positive cancersInitial breast cancer diagnosisReceptor-positive breast cancerMost postmenopausal womenUpfront aromatase inhibitorsYears of tamoxifenAdjuvant endocrine therapyDisease-free survivalReceptor-positive cancersCommon tumor subtypeBreast cancer diagnosisPostmenopausal settingEndocrine treatmentOverall survivalDisease recurrenceRandomized trialsAvailable trialsIndividual patientsHigh riskTumor subtypesAdherence to Initial Adjuvant Anastrozole Therapy Among Women With Early-Stage Breast Cancer
Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to Initial Adjuvant Anastrozole Therapy Among Women With Early-Stage Breast Cancer. Journal Of Clinical Oncology 2008, 26: 556-562. PMID: 18180462, DOI: 10.1200/jco.2007.11.5451.Peer-Reviewed Original ResearchConceptsEarly-stage breast cancerAdjuvant anastrozole therapyBreast cancerAnastrozole therapyProgram data setHealth programsAdjuvant aromatase inhibitorsOral hormonal therapyMonths of therapyEarly-stage diseaseIdentification of patientsProportion of daysLongitudinal claims dataHormonal therapyMean adherenceDevelopment of interventionsAdherence estimatesContinuous eligibilityPrescription claimsAromatase inhibitorsClaims dataTherapyCancerObservation periodWomen
2002
Adherence to Therapy With Oral Antineoplastic Agents
Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to Therapy With Oral Antineoplastic Agents. Journal Of The National Cancer Institute 2002, 94: 652-661. PMID: 11983753, DOI: 10.1093/jnci/94.9.652.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdolescentAntineoplastic AgentsChildClinical Trials as TopicDrug UtilizationHumansNeoplasmsPatient ComplianceConceptsOral antineoplastic agentsAntineoplastic agentsOral antineoplastic therapyOral anticancer agentsAssessment of adherenceStudy of adherencePrediction of adherenceImplementation of interventionsChemotherapy recommendationsOral medicationsPrescribed regimensClinical outcomesPatient adherencePediatric populationAdherence ratesPoor adherenceAntineoplastic therapyAdherence issuesClinical trialsCancer preventionPhysician's officeAdherence behaviorAvailable evidenceAdherenceCertain populations